January 1, 2026
Headlines

Biopharma

Aeovian Pharmaceuticals Secures $55 Million to Revolutionize Treatment for Refractory Tuberous Sclerosis Complex Epilepsy

Editor09 mins

Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company focused on restoring cellular metabolic quality control, has successfully closed an oversubscribed $55 million Series B financing. This substantial investment is earmarked to propel the development of its lead candidate, AV078, a first-in-class, CNS-penetrant selective mTORC1 inhibitor, and finance the completion of its crucial Phase 2 proof-of-concept study. The…

Read More

Attivare Therapeutics Secures $6.6 Million Grant to Advance Long-Lasting Malaria Vaccine Innovation

Editor05 mins

Attivare Therapeutics, Inc. has been awarded a $6.6 million grant from the Gates Foundation to accelerate development of a next-generation malaria vaccine designed for durability, affordability, and global accessibility. The funding supports advancement of the company’s proprietary ATTimmune™ bioscaffold platform, with a focus on populations in low- and middle-income countries where cold-chain logistics and repeat…

Read More

TRIANA Biomedicines Secures Oversubscribed $120 Million Series B to Advance Molecular Glue Degrader Pipeline

Editor06 mins

TRIANA Biomedicines said on Thursday it had closed an oversubscribed $120 million Series B financing, strengthening its push to bring a new class of molecular glue degraders into the clinic, including its lead candidate, TRI-611, for patients with ALK-positive non-small cell lung cancer (NSCLC). The round was co-led by new investors (Ascenta Capital) and (Bessemer…

Read More

Summit Therapeutics Raises $500 Million in Private Placement to Propel Ivonescimab’s Clinical Advancement and Solidify Leadership in Next-Gen Oncology

Editor06 mins

In a significant capital infusion, Summit Therapeutics Inc., a Miami-headquartered biopharmaceutical company specializing in oncology, has successfully raised $500 million through a private placement of approximately 26.68 million common shares priced at $18.74 each—the closing price on October 21, 2025. The offering was led by a blend of institutional biotech investors and company insiders, signaling…

Read More

InVirtuoLabs Nets €2.85M to Revolutionize Drug Discovery with AI Precision

Editor06 mins

A beacon of innovation has emerged from the serene shores of Lugano, as InVirtuoLabs secures €2.85 million in its inaugural funding round. This Swiss biotech pioneer, dedicated to reshaping the future of pharmaceuticals, is set to harness artificial intelligence to slash the staggering costs and timelines that have long burdened drug development. With this capital,…

Read More

Tolerance Bio, Inc. Secures $17.2 Million Seed Financing to Revolutionize Thymus-Based Therapies for Immune Disorders

Editor05 mins

In a significant development for the biopharmaceutical landscape, Tolerance Bio, Inc. has announced the successful closure of its oversubscribed $17.2 million seed financing round. Spearheaded by Columbus Venture Partners, this funding will accelerate the company’s innovative work on thymus preservation, regeneration, and manipulation therapies aimed at treating a range of immune-mediated diseases. Founded by industry…

Read More

RevOpsis Therapeutics Secures $1.8M NEI SBIR Grant to Propel Innovative Ophthalmic Therapies

Editor05 mins

In a significant advancement for ophthalmic medicine, RevOpsis Therapeutics, a pioneering biopharmaceutical firm, has been awarded a Small Business Innovation Research (SBIR) grant exceeding $1.8 million from the National Eye Institute (NEI), part of the National Institutes of Health (NIH). This funding will bolster the development of their lead asset, RO-104, aimed at treating neovascular…

Read More

Bio-Sourcing Secures €12.5M from EIC Accelerator to Revolutionize Biotherapeutic Production

Editor05 mins

In a remarkable advancement for sustainable biopharmaceuticals, Belgian company Bio-Sourcing has successfully secured €12.5 million from the European Innovation Council (EIC) Accelerator. This funding comprises €2.5 million in grants and €10 million in equity, aimed at enhancing the company’s innovative BioMilk platform, which is poised to redefine the production of biotherapeutics, particularly monoclonal antibodies. The…

Read More

Cellino Secures $25 Million Grant from ARPA-H to Revolutionize Biomanufacturing for Personalized Regenerative Medicine

Editor05 mins

In a landmark development for the field of regenerative medicine, Cellino Biotech, Inc. has been awarded up to $25 million in funding from the Advanced Research Projects Agency for Health (ARPA-H), a division within the U.S. Department of Health and Human Services. This grant will significantly advance Cellino’s NEBULA, a cutting-edge biomanufacturing technology designed to…

Read More

PhoreMost Secures £33M in Series B Funding to Propel ‘Drugging the Undruggable’ Innovation

Editor05 mins

PhoreMost, the cutting-edge UK biopharmaceutical enterprise specializing in innovative drug development, has successfully closed an impressive £33 million Series B funding round. This latest round, which saw significant oversubscription, underscores the growing confidence in PhoreMost’s pioneering approach to addressing previously untargetable disease mechanisms. Central to PhoreMost’s strategy is their revolutionary SITESEEKER platform. This technology excels…

Read More